Stryker Corporation (SYK) - Stock Report

The latest proof is mixed rather than broken. In Q1 2026, reported net sales rose 2.6% to $6.0 bn and organic net sales rose 2.4%, with management explicitly pointing to recovery from the March 2026 cyber incident rather than a clean demand quarter. Reported operating margin improved to 15.5%, while adjusted operating margin fell 180 bps to 21.1%, so the quarter shows resilience but not yet margin-quality proof. Operating cash flow was $581 m against $166 m of capital expenditures, leaving a post-capex cash signal of roughly $415 m versus $337 m of dividends and no share repurchases. The quarter should not be annualized mechanically: it includes cyber-related disruption, a recast segment structure, and ongoing integration work from Inari, followed by the post-quarter AVS acquisition in May 2026.

The key macro issue is not healthcare demand in the abstract, but whether elective procedure volume and hospital budgets pass through Stryker’s reported margin and post-capex cash flow: if volumes reaccelerate and vascular integration becomes cash-contributive, the company can earn into a full valuation; if disruption, pricing pressure or integration costs persist, adjusted growth will not be enough.

Stryker is a global medical-technology company built around two reportable segments: MedSurg and Neurotechnology, and Orthopaedics. MedSurg and Neurotechnology includes surgical instruments, endoscopy and communications systems, patient handling, emergency medical equipment, intensive-care disposables, neurovascular products and the Vascular franchise. Orthopaedics is centered on hip, knee, trauma and extremities implants plus Ortho Tech, which now groups Mako, orthopedic instruments, power tools, cutting accessories and enabling technologies.

The value stack is not just a list of devices. Orthopaedics monetizes procedure volume, surgeon relationships, implant pull-through and robotic workflow adoption. Mako and Ortho Tech matter because enabling technology can raise switching costs, support implant mix and deepen hospital relationships beyond a single implant sale. MedSurg and Neurotechnology adds faster-cycle equipment, disposables and vascular products that diversify the group away from large-joint replacement alone.

The 2025 Inari acquisition gave Stryker a larger position in peripheral vascular intervention, and the May 2026 AVS acquisition adds a next-generation intravascular lithotripsy platform under development. That makes vascular a more explicit value-bridge engine: it can extend Stryker's growth runway, but it also raises the burden on integration, clinical adoption, amortization absorption and cash returns on acquired capital.